Rigel Pharmaceuticals (RIGL) Short-term Investments (2010 - 2026)

Rigel Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $122.3 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 289.76% year-over-year to $122.3 million in Q1 2026; TTM through Mar 2026 was $122.3 million, a 289.76% increase from a year earlier, with the FY2025 full-year figure at $114.4 million, up 455.89% from the prior year.
• Short-term Investments advanced to $122.3 million in Q1 2026 per RIGL's latest filing, from $114.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $122.3 million in Q1 2026 and bottomed at $9.4 million in Q3 2024.
• The 5-year median for Short-term Investments is $31.4 million (2025), against an average of $46.1 million.
• Across the five-year window, Short-term Investments plunged 77.82% in 2023 and soared 840.45% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $33.7 million in 2022, then fell by 28.45% to $24.1 million in 2023, then slipped by 14.79% to $20.6 million in 2024, then surged by 455.89% to $114.4 million in 2025, then climbed by 6.91% to $122.3 million in 2026.
• Per Business Quant, the three latest RIGL Short-term Investments figures stand at $122.3 million (Q1 2026), $114.4 million (Q4 2025), and $88.6 million (Q3 2025).